World Wires · story 28770 · unverified · 1 source(s)

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

October 8, 2026, 7:00 AM CET

Open in the desk

Coverage

• argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease GlobeNewswire: public companies · tier D · clear net · 2026-10-08 05:00 UTC

What this site indexes